US 11,052,086 B2
2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
Michael Nicholas Greco, Lansdale, PA (US); Michael John Costanzo, Warminster, PA (US); Michael Alan Green, Easton, PA (US); Jirong Peng, Mequon, WI (US); Victoria Lynn Wilde, Montclair, NJ (US); and Don Zhang, Princeton, NJ (US)
Assigned to BETA PHARMA, INC., Wilmington, DE (US)
Appl. No. 16/300,949
Filed by Beta Pharma, Inc., Wilmington, DE (US)
PCT Filed May 11, 2017, PCT No. PCT/US2017/032066
§ 371(c)(1), (2) Date Nov. 12, 2018,
PCT Pub. No. WO2017/197062, PCT Pub. Date Nov. 16, 2017.
Claims priority of provisional application 62/334,830, filed on May 11, 2016.
Prior Publication US 2019/0365755 A1, Dec. 5, 2019
Int. Cl. A61K 31/506 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/506 (2013.01) [A61P 35/04 (2018.01)] 7 Claims
1. A method of treating brain cancer in a subject, comprising administering to the subject a therapeutically effective amount of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate (formula 1·Ms):

OG Complex Work Unit Chemistry